Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology company focused on rare neurological diseases, has priced a public offering of 3,500,000 shares of common stock at $30.00 per share.

The company also offered pre-funded warrants to purchase up to 666,666 shares at $29.999999 per warrant, with an exercise price of $0.000001 per share. The warrants are exercisable immediately.

Gross proceeds from the offering are expected to total approximately $125 million before underwriting discounts, commissions, and other expenses, excluding any exercise of the underwriters' option to purchase additional shares.

Neurogene has granted underwriters a 30-day option to purchase up to an additional 624,999 shares at the public offering price, less underwriting discounts and commissions.

The offering is expected to close on July 2, 2026, subject to customary closing conditions.

Leerink Partners, Stifel, Guggenheim Securities, LifeSci Capital, and William Blair are serving as joint bookrunning managers for the offering.

The offering is made under a shelf registration statement filed with the Securities and Exchange Commission on March 24, 2025, which was declared effective on April 4, 2025.